1
|
Muñoz de Rueda P, Jiménez-Ruiz SM, Quiles R, Pavón-Castillero EJ, Muñoz-Gámez JA, Casado J, Gila A, Ruiz-Extremera A, Salmerón J. The antigenic variability of HCV in viral HLA-Ag binding is related to the activation of the host immune response. Sci Rep 2017; 7:15513. [PMID: 29138492 PMCID: PMC5686107 DOI: 10.1038/s41598-017-15605-0] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/02/2017] [Accepted: 10/23/2017] [Indexed: 01/17/2023] Open
Abstract
Our previous data show that hepatitis C virus (HCV) genotype 1 patients expressing the HLA-DQB1 * 0301 allele have a combined response probability of 69%, while the remaining 31% do not respond, probably because the HCV immunodominant epitope (IE) against the DQB1 * 0301 allele is mutated. HCV IE (region sequenced in NS3 is a region encoding aa 1253–1272) from 37 patients (21 Sustained Virological Response, SVR; 16 non-SVR) HLA-DQB1 * 0301+, were analysed by pyrosequencing. In vitro cultures were also determined by CD4+ proliferation, using non-mutated IE (wild-type synthetic peptide) and synthetic mutated peptide. The pyrosequencing study revealed 34 different haplotypes. The SVR patients had fewer haplotypes (P = 0.07), mutations/haplotypes (P = 0.01) and polymorphic sites (P = 0.02) than non-SVR. Three polymorphic sites were associated with the non-SVR patients: haplotype 7 (L5P); haplotype 11 (L7P); and haplotype 15, (L15S) (P = 0.02). The in vitro study (n = 7) showed that in 4/7 patients (Group 1) the CD4+ proliferation obtained with wild-type synthetic peptide was higher than that obtained with the negative control and with the synthetic mutated peptide (P = 0.039). However, in the remaining 3/7 patients (Group 2) this pattern was not observed (P = 0.7). Our findings suggest that HLA-DQB1 * 0301+ patients with high antigenic variability in HCV IE (NS31253-1272) have a lower SVR rate, due to reduced CD4+ proliferation as a result of incorrect viral HLA-Ag binding.
Collapse
Affiliation(s)
- P Muñoz de Rueda
- Clinical Management Unit of Digestive Diseases, Research Unit, San Cecilio University Hospital, Granada, 18012, Spain.,CIBER for Liver and Digestive Disease (CIBERehd), Instituto de Salud Carlos III, Madrid, 28029, Spain.,Instituto De Investigación Biosanitaria de Granada (ibs.GRANADA), Granada, 18012, Spain
| | | | - R Quiles
- Clinical Management Unit of Digestive Diseases, Research Unit, San Cecilio University Hospital, Granada, 18012, Spain. .,CIBER for Liver and Digestive Disease (CIBERehd), Instituto de Salud Carlos III, Madrid, 28029, Spain. .,Instituto De Investigación Biosanitaria de Granada (ibs.GRANADA), Granada, 18012, Spain.
| | - E J Pavón-Castillero
- Clinical Management Unit of Digestive Diseases, Research Unit, San Cecilio University Hospital, Granada, 18012, Spain.,Instituto De Investigación Biosanitaria de Granada (ibs.GRANADA), Granada, 18012, Spain
| | - J A Muñoz-Gámez
- Clinical Management Unit of Digestive Diseases, Research Unit, San Cecilio University Hospital, Granada, 18012, Spain.,Instituto De Investigación Biosanitaria de Granada (ibs.GRANADA), Granada, 18012, Spain
| | - J Casado
- Clinical Management Unit of Digestive Diseases, Research Unit, San Cecilio University Hospital, Granada, 18012, Spain.,Instituto De Investigación Biosanitaria de Granada (ibs.GRANADA), Granada, 18012, Spain
| | - A Gila
- Clinical Management Unit of Digestive Diseases, Research Unit, San Cecilio University Hospital, Granada, 18012, Spain.,CIBER for Liver and Digestive Disease (CIBERehd), Instituto de Salud Carlos III, Madrid, 28029, Spain.,Instituto De Investigación Biosanitaria de Granada (ibs.GRANADA), Granada, 18012, Spain
| | - A Ruiz-Extremera
- CIBER for Liver and Digestive Disease (CIBERehd), Instituto de Salud Carlos III, Madrid, 28029, Spain.,Instituto De Investigación Biosanitaria de Granada (ibs.GRANADA), Granada, 18012, Spain.,Paediatric Unit, San Cecilio University Hospital and Virgen de las Nieves University Hospital, Granada, 18012, Spain.,Paediatric Department, Granada University, Granada, 18016, Spain
| | - J Salmerón
- Clinical Management Unit of Digestive Diseases, Research Unit, San Cecilio University Hospital, Granada, 18012, Spain.,CIBER for Liver and Digestive Disease (CIBERehd), Instituto de Salud Carlos III, Madrid, 28029, Spain.,Instituto De Investigación Biosanitaria de Granada (ibs.GRANADA), Granada, 18012, Spain.,Medicine Departament, Granada University, Granada, 18016, Spain
| |
Collapse
|
2
|
Ruiz-Extremera A, Pavón-Castillero EJ, Florido M, Muñoz de Rueda P, Muñoz-Gámez JA, Casado J, Carazo A, Quiles R, Jiménez-Ruiz SM, Gila A, Luna JD, León J, Salmerón J. Influence of HLA class I, HLA class II and KIRs on vertical transmission and chronicity of hepatitis C virus in children. PLoS One 2017; 12:e0172527. [PMID: 28225833 PMCID: PMC5321427 DOI: 10.1371/journal.pone.0172527] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/26/2016] [Accepted: 02/06/2017] [Indexed: 12/12/2022] Open
Abstract
Background & aim There is evidence that maternal viral load of HCV during delivery influences the risk for Mother-to-child transmission (MTCT), but this does not explain all cases. We study the role of the immunogenetic profile (HLA, KIRs and KIR-ligand binding) of mothers and children in HCV-MTCT and in chronicity in the children. Methodology 79 HCV-RNA (+) mothers and their 98 children were included. 24 children were infected, becoming chronic in 8 cases and clearing in 16. HLA-class-I and II and KIRs were determined by Luminex. Results MTCT study: The presence of HLA-C1-ligand in mothers and/or their children reduces the risk of transmission (mothers: Pc = 0.011, children: P = 0.033), whereas the presence of HLA-C2C2-ligand in mothers increases it (Pc = 0.011). In children KIR2DL3-HLA-C1 is a protector factor (Pc = 0.011). Chronicity in children study: Maternal DQA1*01 allele (Pc = 0.027), KIR2DS1 (Pc = 0.011) or KIR3DS1 (Pc = 0.011) favours chronicity in the child. The presence of the DQB1*03 allele (Pc = 0.027) and KIR2DS3 (P = 0.056) in the child and homozygosity for KIR3DL1/3DL1 (Pc = 0.011) and for the HLA-Bw4/Bw4 ligand (P = 0.027) is associated with viral clearance, whereas the presence of HLA-Bw6 ligand (P = 0.027), the binding of KIR3DS1-HLA-Bw4 (P = 0.037) and heterozygosity for KIR3DL1/3DS1 (Pc = 0.011) favour viral chronicity. Mother/child allele matching: In the joint HLA analysis, matching was greater between mothers and children with chronic infection vs those who had cleared the virus (67%±4.1 vs 57%±1.2, P = 0.003). Conclusions The HLA-C1 ligand in the mother is related to MTCT, while several genetic factors of the mother or child are involved in the chronification or clearance of infection in the child. Matching allelic data is considered to be an indicator of HCV chronicity in the child and can be used as a potential prognostic test. This implies that NK cells may play a previously undocumented role in protecting against MTCT and that both NK cell immunity and adaptive T-cell responses may influence viral clearance in infected children.
Collapse
Affiliation(s)
- A. Ruiz-Extremera
- Paediatric Unit, San Cecilio University Hospital and Virgen de las Nieves University Hospital, Granada, Spain
- Paediatric Department, Granada University, Granada, Spain
- CIBER for Liver and Digestive Disease (CIBERehd), Instituto de Salud Carlos III, Spain
- Instituto de Investigación Biosanitaria de Granada, Spain
| | - E. J. Pavón-Castillero
- Instituto de Investigación Biosanitaria de Granada, Spain
- Clinical Management Unit of Digestive Diseases, Research Unit, San Cecilio University Hospital, Granada, Spain
- * E-mail:
| | - M. Florido
- Clinical Management Unit of Digestive Diseases, Research Unit, San Cecilio University Hospital, Granada, Spain
| | - P. Muñoz de Rueda
- CIBER for Liver and Digestive Disease (CIBERehd), Instituto de Salud Carlos III, Spain
- Instituto de Investigación Biosanitaria de Granada, Spain
- Clinical Management Unit of Digestive Diseases, Research Unit, San Cecilio University Hospital, Granada, Spain
| | - J. A. Muñoz-Gámez
- Instituto de Investigación Biosanitaria de Granada, Spain
- Clinical Management Unit of Digestive Diseases, Research Unit, San Cecilio University Hospital, Granada, Spain
| | - J. Casado
- Instituto de Investigación Biosanitaria de Granada, Spain
- Clinical Management Unit of Digestive Diseases, Research Unit, San Cecilio University Hospital, Granada, Spain
| | - A. Carazo
- Instituto de Investigación Biosanitaria de Granada, Spain
- Clinical Management Unit of Digestive Diseases, Research Unit, San Cecilio University Hospital, Granada, Spain
| | - R. Quiles
- CIBER for Liver and Digestive Disease (CIBERehd), Instituto de Salud Carlos III, Spain
- Instituto de Investigación Biosanitaria de Granada, Spain
- Clinical Management Unit of Digestive Diseases, Research Unit, San Cecilio University Hospital, Granada, Spain
| | - S. M. Jiménez-Ruiz
- Clinical Management Unit of Digestive Diseases, Research Unit, San Cecilio University Hospital, Granada, Spain
- Medicine Department, Granada University, Granada, Spain
| | - A. Gila
- CIBER for Liver and Digestive Disease (CIBERehd), Instituto de Salud Carlos III, Spain
- Instituto de Investigación Biosanitaria de Granada, Spain
- Clinical Management Unit of Digestive Diseases, Research Unit, San Cecilio University Hospital, Granada, Spain
| | - J. D. Luna
- Instituto de Investigación Biosanitaria de Granada, Spain
- Biostatistic Department, Granada University, Granada, Spain
| | - J. León
- CIBER for Liver and Digestive Disease (CIBERehd), Instituto de Salud Carlos III, Spain
- Instituto de Investigación Biosanitaria de Granada, Spain
- Clinical Management Unit of Digestive Diseases, Research Unit, San Cecilio University Hospital, Granada, Spain
| | - J. Salmerón
- CIBER for Liver and Digestive Disease (CIBERehd), Instituto de Salud Carlos III, Spain
- Instituto de Investigación Biosanitaria de Granada, Spain
- Clinical Management Unit of Digestive Diseases, Research Unit, San Cecilio University Hospital, Granada, Spain
- Medicine Department, Granada University, Granada, Spain
| |
Collapse
|
3
|
Carrillo-Alascio PL, Sabio JM, Núñez-Torres MI, López E, Muñoz-Gámez JA, Hidalgo-Tenorio C, Jáimez L, Martín J, Jiménez-Alonso J. In-vitro radiosensitivity in patients with systemic lupus erythematosus. Lupus 2009; 18:645-9. [PMID: 19433466 DOI: 10.1177/0961203309103150] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2023]
Abstract
To determine the "in-vitro" intrinsic cell radiosensitivity (RS) as a risk indicator of radiation-related side-effects in patients with systemic lupus erythematosus (SLE) compared with healthy subjects (control group). Moreover, we elucidated if clinical, therapeutic and biological parameters could affect the "in-vitro" intrinsic RS in patients with SLE. Intrinsic RS was determined by the quantification of the initial radiation-induced DNA double-strand breaks in peripheral lymphocytes, measured by pulsed-field gel electrophoresis from 52 patients with SLE and a control group consisting of 48 sex- and age-matched healthy subjects. No difference in intrinsic RS was found among both groups. However, SLE patients with anaemia, increased erythrocyte sedimentation rate and those with positive result for anti-La/SSB and anti-RNP antibodies showed significantly higher DNA double-strand breaks than those without them. In our study, patients with SLE did not have a higher intrinsic RS than healthy subjects. According to these results, and with the caution of being a limited laboratory study, the use of radiotherapy should not be avoided in patients with SLE when it is clinically needed.
Collapse
Affiliation(s)
- P L Carrillo-Alascio
- Unidad de Enfermedades Autoinmunes Sistémicas, Servicio de Medicina Interna, Hospital Universitario Virgen de las Nieves, Granada, Spain
| | | | | | | | | | | | | | | | | |
Collapse
|
4
|
Aguilar-Quesada R, Muñoz-Gámez JA, Martín-Oliva D, Peralta-Leal A, Quiles-Pérez R, Rodríguez-Vargas JM, Ruiz de Almodóvar M, Conde C, Ruiz-Extremera A, Oliver FJ. Modulation of transcription by PARP-1: consequences in carcinogenesis and inflammation. Curr Med Chem 2007; 14:1179-87. [PMID: 17504138 DOI: 10.2174/092986707780597998] [Citation(s) in RCA: 105] [Impact Index Per Article: 6.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
Post-translational modification of proteins by poly(ADP-ribosyl)ation is involved in the regulation of a number of biological functions. While an 18 member superfamily of poly(ADP-ribose) polymerases (PARP)s has been described PARP-1 accounts for more than 90% of the poly(ADP-ribosyl)ating capacity of the cells. PARP-1 act as a DNA nick sensor and is activated by DNA breaks to cleave NAD(+) into nicotinamide and ADP-ribose to synthesize long branching poly(ADP-ribose) polymers (PAR) covalently attached to nuclear acceptor proteins. Whereas activation of PARP-1 by mild genotoxic stimuli facilitate DNA repair and cell survival, severe DNA damage triggers different pathways of cell death including PARP-mediated cell death through the translocation of apoptosis inducing factor (AIF) from the mitochondria to the nucleus. PAR and PARP-1 have also been described as having a function in transcriptional regulation through their ability to modify chromatin-associated proteins and as a cofactor of different transcription factors, most notably NF-kappaB and AP-1. Pharmacological inhibition or genetic ablation of PARP-1 not only provided remarkable protection from tissue injury in various oxidative stress-related disease models but it result in a clear benefit in the treatment of cancer by different mechanisms including selective killing of homologous recombination-deficient tumor cells, down regulation of tumor-related gene expression and decrease in the apoptotic threshold in the co-treatment with chemo and radiotherapy. We will summarize in this review the current findings and concepts for the role of PARP-1 and poly(ADP-ribosyl)ation in the regulation of transcription, oxidative stress and carcinogenesis.
Collapse
Affiliation(s)
- R Aguilar-Quesada
- Instituto de Parasitología y Biomedicina López Neyra, CSIC, Granada, Spain
| | | | | | | | | | | | | | | | | | | |
Collapse
|
5
|
Siles E, Martinez-Lara E, Núñez MI, Muñoz-Gámez JA, Martín-Oliva D, Valenzuela MT, Peinado MA, Ruiz de Almodóvar JM, Javier Oliver F. PARP-1-dependent 3-nitrotyrosine protein modification after DNA damage. J Cell Biochem 2005; 96:709-15. [PMID: 16052507 DOI: 10.1002/jcb.20570] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
3-nitrotyrosine (NO2-Tyr) is thought to be a specific marker of cell injury during oxidative damage. We have evaluated the role of poly(ADP-ribose)polymerase-1 (PARP-1) in protein nitration after treatment of immortalized fibroblasts parp-1+/+ and parp-1-/- with the alkylating agent 2'-methyl-2'-nitroso-urea (MNU). Both cell lines showed increased iNOS expression following MNU treatment in parallel with a selective induction of tyrosine nitration of different proteins. PARP-1 deficient cells displayed a delayed iNOS accumulation, reduced number of nitrated proteins, and a lower global nitrotyrosine "footprint." We have identified the mitochondrial compartment as the major site of oxidative stress during DNA damage, being MnSOD one of the NO2-Tyr-modified proteins, but not in parp-1-/- cells. These results suggest that NO-derived injury can be modulated by proteins involved in the response to genotoxic damage, such as PARP-1, and may account for the limited oxidative injury in parp-1 knockout mice during carcinogenesis and inflammation.
Collapse
Affiliation(s)
- E Siles
- Dpto. Biología Experimental, Universidad de Jaén, Spain
| | | | | | | | | | | | | | | | | |
Collapse
|